Sorafenib (Nexavar^ⓡ, BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Sorafenib (Nexavar^ⓡ, BAY 43-9006) is a novel, orally administered multi-kinase inhibitor that has recently been approved for the treatment of metastatic renal cell carcinoma. It is also used to delay disease progression in patients with advanced solid organ malignancies and metastatic melanoma. Sorafenib is associated with a relatively high incidence of dermatologic adverse events. The commonly occurring dermatologic adverse events associated with sorafenib include hand-foot skin reaction,facial erythema, splinter subungual hemorrhages, alopecia,pruritus and xerosis. We report here on a case of a 50-year-old man who was diagnosed with metastatic hepatocellular carcinoma. He developed both facial erythema and hand-foot skin reaction after the administration of sorafenib. (Ann Dermatol 23(1) 119∼122, 2011)
Abstract
Sorafenib (Nexavar^ⓡ, BAY 43-9006) is a novel, orally administered multi-kinase inhibitor that has recently been approved for the treatment of metastatic renal cell carcinoma. It is also used to delay disease progression in patients with advanced solid organ malignancies and metastatic melanoma. Sorafenib is associated with a relatively high incidence of dermatologic adverse events. The commonly occurring dermatologic adverse events associated with sorafenib include hand-foot skin reaction,facial erythema, splinter subungual hemorrhages, alopecia,pruritus and xerosis. We report here on a case of a 50-year-old man who was diagnosed with metastatic hepatocellular carcinoma. He developed both facial erythema and hand-foot skin reaction after the administration of sorafenib. (Ann Dermatol 23(1) 119∼122, 2011)
참고문헌 (13)
- Kane RC, "Sorafenib for the treatment of advanced renal cell carcinoma", Clin Cancer Res, 12, pp.7271~7278 (2006)
- Llovet J, "Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)", J Clin Oncol, 25, pp.1~ (2007)
- Ratain MJ, "Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma", J Clin Oncol, 24, pp.2505~2512 (2006)
- Strumberg D, "Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome", Eur J Cancer, 42, pp.548~556 (2006)
- Wilhelm SM, "BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF", MEK, Cancer Res, pp.2004, 64[DOI]
- Ito Y, "Activation of mitogen-activated protein kinases", extracellular signal-regulated kinases in human hepatocellular carcinoma, 1998, pp.27, 951~958
- Autier J, "Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor", Arch Dermatol, 144, pp.886~892 (2008)
- Susser WS, "Mucocutaneous reactions to chemotherapy", J Am Acad Dermatol, 40, pp.367~398 (1999)
- Lacouture ME, "Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib", Oncologist, 13, pp.1001~1011 (2008)
- Chu D, "Risk of hand-foot skin reaction with sorafenib: a systematic review and metaanalysis", Acta Oncol, 47, pp.176~186 (2008)
- Lee WJ, "Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib", Br J Dermatol, 161, pp.1045~1051 (2009)
- 박지호, "Sorafenib (NexavarⓇ, BAY 43-9006) 복용 후 발생한 피부 부작용 1예", 대한피부과학회지, 46(1), pp.141~143 (2008), 대한피부과학회
- 김학주, "SorafenibⓇ 복용 후 발생한 백혈구 파쇄성 혈관염 1예", 대한피부과학회지, 46(5), pp.648~651 (2008), 대한피부과학회